High-performance liquid chromatographic method for the determination of dasatinib in rabbit plasma using fluorescence detection and its application to a pharmacokinetic study

被引:27
作者
Kassem, Mohammed G. [1 ]
Ezzeldin, Essam [2 ]
Korashy, Hesham M. [3 ]
Mostafa, Gamal A. E. [1 ]
机构
[1] King Saud Univ, Coll Pharm, Dept Pharmaceut Chem, Riyadh 11451, Saudi Arabia
[2] King Saud Univ, Coll Pharm, Drug Bioavailabil Unite, Riyadh 11451, Saudi Arabia
[3] King Saud Univ, Coll Pharm, Dept Pharmacol & Toxicol, Riyadh 11451, Saudi Arabia
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2013年 / 939卷
关键词
Dasatinib; HPLC; Method of validation; Rabbit plasma; Pharmacokinetic study; TYROSINE KINASE INHIBITORS; MASS-SPECTROMETRY; IMATINIB; VALIDATION; BMS-354825; SRC; NILOTINIB; CANCER;
D O I
10.1016/j.jchromb.2013.09.012
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A highly selective, sensitive, and rapid high performance liquid chromatographic (HPLC) method has been developed and validated to quantify dasatinib, a tyrosine kinase inhibitor, in rabbit plasma. Montelukast was used as internal standard (IS). Dasatinib and IS were extracted by deproteinization technique, followed by injection of aliquot of supernatant into chromatographic system. Chromatographic separation was achieved on a reversed phase C18 column with a mobile phase of 0.02 M potassium dihydrogen phosphate:methanol (10:90, v/v) pumped at flow rate of 2.0 mL/min. The analytes were detected at 340 and 374 nm for excitation and emission, respectively. The assay exhibited a linear range of 50.0-3000 ng/mL, with a lower detection limit of 15.0 ng/mL. The method was statistically validated for linearity, accuracy, precision, selectivity and stability following FDA guidelines. The intra- and inter-assay coefficients of variation did not exceed 13.5% from the nominal concentration. The accuracy of dasatinib was within +/- 15% of the theoretical value. The assay has been applied successfully in a pharmacokinetic study. (C) 2013 Elsevier B.V. All rights reserved.
引用
收藏
页码:73 / 79
页数:7
相关论文
共 24 条
[1]  
[Anonymous], 2001, Guidance for industry, bioanalytical method validation
[2]   Simple methodology for the therapeutic drug monitoring of the tyrosine kinase inhibitors dasatinib and imatinib [J].
Birch, M. ;
Morgan, P. E. ;
Handley, S. ;
Ho, A. ;
Ireland, R. ;
Flanagan, R. J. .
BIOMEDICAL CHROMATOGRAPHY, 2013, 27 (03) :335-342
[3]   Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS [J].
Bouchet, Stephane ;
Chauzit, Emmanuelle ;
Ducint, Dominique ;
Castaing, Nadege ;
Canal-Raffin, Mireille ;
Moore, Nicholas ;
Titier, Karine ;
Molimard, Mathieu .
CLINICA CHIMICA ACTA, 2011, 412 (11-12) :1060-1067
[4]   Validation of PDGFRβ and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma:: preclinical efficacy of the novel, orally available inhibitor dasatinib [J].
Coluccia, Addolorata Maria Luce ;
Cirulli, Teresa ;
Neri, Paola ;
Mangieri, Domenica ;
Colanardi, Maria Cristina ;
Gnoni, Antonio ;
Di Renzo, Nicola ;
Dammacco, Franco ;
Tassone, Pierfrancesco ;
Ribatti, Domenico ;
Gambacorti-Passerini, Carlo ;
Vacca, Angelo .
BLOOD, 2008, 112 (04) :1346-1356
[5]   HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC) [J].
D'Avolio, Antonio ;
Simiele, Marco ;
De Francia, Silvia ;
Ariaudo, Alessandra ;
Baietto, Lorena ;
Cusato, Jessica ;
Fava, Carmen ;
Saglio, Giuseppe ;
Di Carlo, Francesco ;
Di Perri, Giovanni .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2012, 59 :109-116
[6]   New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma [J].
De Francia, Silvia ;
D'Avolio, Antonio ;
De Martino, Francesca ;
Pirro, Elisa ;
Baietto, Lorena ;
Siccardi, Marco ;
Simiele, Marco ;
Racca, Silvia ;
Saglio, Giuseppe ;
Di Carlo, Francesco ;
Di Perri, Giovanni .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2009, 877 (18-19) :1721-1726
[7]   HPLC-DAD protein kinase inhibitor analysis in human serum [J].
Dziadosz, Marek ;
Lessig, Ruediger ;
Bartels, Heidemarie .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2012, 893 :77-81
[8]   Src in cancer: deregulation and consequences for cell behaviour [J].
Frame, MC .
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2002, 1602 (02) :114-130
[9]   A validated LC-MS/MS assay for the simultaneous determination of the anti-leukemic agent dasatinib and two pharmacologically active metabolites in human plasma: Application to a clinical pharmacokinetic study [J].
Furlong, Michael T. ;
Agrawal, Shruti ;
Hawthorne, Dara ;
Lago, Michael ;
Unger, Steve ;
Krueger, Linda ;
Stouffer, Bruce .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2012, 58 :130-135
[10]   Protein tyrosine kinase structure and function [J].
Hubbard, SR ;
Till, JH .
ANNUAL REVIEW OF BIOCHEMISTRY, 2000, 69 :373-398